secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001628280-23-026987
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track
----------------------------------------------------------------------------

- Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.
- Cash $148.2M; secured $50M term loan from Hercules Capital, $28.1M drawn.
- COMP360 Phase 3 TRD trials on track; topline data expected summer 2024 (COMP 005) and mid-2025 (COMP 006).
- AMA accepted CPT III code for in-person psychedelic therapy support, aligning with COMP360 requirements.
- ATAI exercised demand registration rights for 7,935,663 shares; filing required within 45 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/0001628280-23-026987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023026987/cmps-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer